304 related articles for article (PubMed ID: 15033678)
41. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Hotte SJ; Oza A; Winquist EW; Moore M; Chen EX; Brown S; Pond GR; Dancey JE; Hirte HW
Ann Oncol; 2006 Feb; 17(2):334-40. PubMed ID: 16284058
[TBL] [Abstract][Full Text] [Related]
42. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
43. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
44. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
45. Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors.
Giantonio BJ; Derry C; McAleer C; McPhillips JJ; O'Dwyer PJ
Clin Cancer Res; 2004 Feb; 10(4):1282-8. PubMed ID: 14977826
[TBL] [Abstract][Full Text] [Related]
46. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
[TBL] [Abstract][Full Text] [Related]
47. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
48. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
49. Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Baird RD; Kitzen J; Clarke PA; Planting A; Reade S; Reid A; Welsh L; López Lázaro L; de las Heras B; Judson IR; Kaye SB; Eskens F; Workman P; deBono JS; Verweij J
Mol Cancer Ther; 2009 Jun; 8(6):1430-7. PubMed ID: 19509256
[TBL] [Abstract][Full Text] [Related]
50. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
51. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of dolastatin-10 in patients with advanced breast cancer.
Perez EA; Hillman DW; Fishkin PA; Krook JE; Tan WW; Kuriakose PA; Alberts SR; Dakhil SR
Invest New Drugs; 2005 Jun; 23(3):257-61. PubMed ID: 15868383
[TBL] [Abstract][Full Text] [Related]
53. Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Massard C; Margetts J; Amellal N; Drew Y; Bahleda R; Stephens P; Armand JP; Calvert H; Soria JC; Coronado C; Kahatt C; Alfaro V; Siguero M; Fernández-Teruel C; Plummer R
Invest New Drugs; 2013 Jun; 31(3):623-30. PubMed ID: 22688291
[TBL] [Abstract][Full Text] [Related]
54. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
55. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
[TBL] [Abstract][Full Text] [Related]
56. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
57. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
[TBL] [Abstract][Full Text] [Related]
58. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.
Schöffski P; Breidenbach I; Krauter J; Bolte O; Stadler M; Ganser A; Wilhelm-Ogunbiyi K; Lentzen H
Eur J Cancer; 2005 Jul; 41(10):1431-8. PubMed ID: 15913988
[TBL] [Abstract][Full Text] [Related]
59. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
60. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Terret C; Zanetta S; Roché H; Schellens JH; Faber MN; Wanders J; Ravic M; Droz JP;
Eur J Cancer; 2003 May; 39(8):1097-104. PubMed ID: 12736109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]